Market Cap | 169.54M | P/E | - | EPS this Y | 91.10% | Ern Qtrly Grth | - |
Income | -98.5M | Forward P/E | 12.79 | EPS next Y | 238.90% | 50D Avg Chg | 23.00% |
Sales | 277.79M | PEG | -0.54 | EPS past 5Y | - | 200D Avg Chg | -57.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | 16.90% | 52W High Chg | -80.00% |
Recommedations | 2.10 | Quick Ratio | 1.42 | Shares Outstanding | 196.22M | 52W Low Chg | 60.00% |
Insider Own | 0.50% | ROA | 1.05% | Shares Float | 194.82M | Beta | 1.00 |
Inst Own | 70.55% | ROE | - | Shares Shorted/Prior | 38.09M/41.73M | Price | 1.79 |
Gross Margin | 61.12% | Profit Margin | -35.46% | Avg. Volume | 2,624,620 | Target Price | 7.59 |
Oper. Margin | 3.49% | Earnings Date | Nov 5 | Volume | 7,117,172 | Change | 5.92% |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Warren Eric | Chief Commercial Off.. Chief Commercial Officer | Sep 20 | Sell | 1.245 | 742 | 924 | 68,318 | 09/21/23 |
Koenig Sheldon L. | President and CEO President and CEO | May 09 | Buy | 1.2596 | 20,000 | 25,192 | 312,816 | 05/10/23 |
Warren Eric | Chief Commercial Off.. Chief Commercial Officer | Mar 07 | Sell | 5.055 | 5,090 | 25,730 | 48,572 | 03/08/23 |
Koenig Sheldon L. | President and CEO President and CEO | Mar 07 | Sell | 5.056 | 5,441 | 27,510 | 194,815 | 03/08/23 |
Foody Joanne M. | Chief Medical Office.. Chief Medical Officer | Mar 07 | Sell | 5.065 | 3,884 | 19,672 | 103,060 | 03/08/23 |
Warren Eric | Chief Commercial Off.. Chief Commercial Officer | Aug 31 | Buy | 7.46 | 1,000 | 7,460 | 54,024 | 08/31/22 |
Koenig Sheldon L. | President and CEO President and CEO | Aug 05 | Buy | 5.8041 | 8,606 | 49,950 | 198,771 | 08/08/22 |
Koenig Sheldon L. | President and CEO President and CEO | Mar 17 | Sell | 4.58 | 571 | 2,615 | 194,717 | 03/18/22 |